COMBATING SEPSIS

WHY DO THEY DIE? DECIPHERING AND QUELLING THE LETHAL CUES OF IMMUNO-INFLAMMATORY RESPONSE IN SEPSIS

Coordinatore	LUDWIG BOLTZMANN GESELLSCHAFT OSTERREICHISCHE VEREINIGUNG ZUR FORDERUNG DER WISSENSCHAFTLICHEN FORSCHUNG    more  Organization address address: NUSSDORFER STRASSE 64/6 city: WIEN postcode: 1090 contact info Titolo: Prof. Nome: Soheyl Cognome: Bahrami Email: send email Telefono: -33110426 Fax: -33110418
Nazionalità Coordinatore	Austria [AT]
Totale costo	100˙000 €
EC contributo	100˙000 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2007-4-3-IRG
Funding Scheme	MC-IRG
Anno di inizio	2007
Periodo (anno-mese-giorno)	2007-12-01   -   2011-11-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	LUDWIG BOLTZMANN GESELLSCHAFT OSTERREICHISCHE VEREINIGUNG ZUR FORDERUNG DER WISSENSCHAFTLICHEN FORSCHUNG  Organization address address: NUSSDORFER STRASSE 64/6 city: WIEN postcode: 1090 contact info Titolo: Prof. Nome: Soheyl Cognome: Bahrami Email: send email Telefono: -33110426 Fax: -33110418	AT (WIEN)	coordinator	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Sepsis is a multifaceted disease that remains a serious clinical problem and causes frequent mortality in human patients worldwide. The proposed project addresses the mechanisms and prevention of early mortality in experimental sepsis. To replicate human sepsis, murine models of live Escherichia coli and Streptococcus pyogenes systemic infusion and cecal ligation and puncture (CLP) peritonitis will be used. The project consists of three aims investigating acute immuno-inflammatory signaling triggered by a septic event: Aim I will study the role and modulation of differential genomic expression upon survival/mortality in gram-negative vs. gram-positive systemic sepsis. Based on the retrospective comparison of outcome in CLP sepsis, Aim II will differentiate between the non-lethal and lethal: (1)-gene/protein expression of inflammatory cytokines and (2)-changes in neurotransmitter fluctuations in different brain regions. Aim III will employ the novel strategy of prospective outcome-based stratification and investigate the effectiveness/mechanism of immuno-modulative anti-inflammatory therapy upon survival in mice predicted to die of acute CLP-induced polymicrobial peritonitis. There is an urgent need for treatments improving outcomes in sepsis and a rise of a new effective, individual patient-based therapy against sepsis is contingent upon exhaustive understanding of its immuno-inflammatory fingerprints. Successful accomplishment of the projected study will contribute to this effort.'